Trial Profile
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-C
- Sponsors United Therapeutics Corporation
- 29 Aug 2022 Results of post-hoc analysis (FREEDOM-C and FREEDOM-C2) assessing efficacy and dose-response relationship of oral treprostinil in pulmonary arterial hypertension patients on monotherapy or dual background therapy, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 18 May 2016 Pooled analysis results from FREEDOM-M, FREEDOM-C, FREEDOM-C2 trials are presented at the 112th International Conference of the American Thoracic Society
- 25 Jun 2014 New trial record